Dydrogesterone

• Post Date:

  Jan 18,2018

• Expiry Date:

  Jul 17,2018

• Detailed Description:

  Cas No. :152-62-5 Dydrogesterone CAS 152-62-5
  Dydrogesterone EINECS:205-806-8
  Dydrogesterone Molecular Formula:C21H28O2
  Dydrogesterone Molecular Weight:312.45
  Dydrogesterone Appearance:White or light yellow crystalline powder
  
  
  Dydrogesterone , is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione.Dydrogesterone
  
  Dydrogesterone has selective progestational activity and does not inhibit ovulation.[3] The greater rigidity of dydrogesterone also positively affects its selectivity,while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10-20 times lower than that of oral micronized progesterone.
  
  The objective behind hormone replacement therapy is to actively increase the circulating levels of estrogen to control hot flushes and to prevent the long-term effects of the menopause, such as bone resorption and unfavourable changes in blood lipids. The administration of 17β-oestradiol halts, or reverses atrophic changes that occur due to the loss of endogenous oestradiol during the menopause.
  
  Estrogen promotes endometrial cell growth and in postmenopausal women with an intact uterus, estrogen monotherapy results in continued endometrial development without the physiological secretory changes normally brought on by progesterone. This action is associated with an increased incidence of endometrial hyperplasia and carcinoma. Additional protection with progestogens is therefore important in patients with an intact uterus who receive estrogen replacement therapy. Dydrogesterone counters the proliferative effect of estrogens on the endometrium and ensures the transition to a secretory pattern and cyclical shedding of the endometrium in serial HRT regimes. Dydrogesterone effectively protects against the ontogenesis of endometrial hyperplasia. Unlike androgenic progestogens, dydrogesterone does not reverse the benefits brought on by 17β-oestradiol on lipid profiles and carbohydrate metabolism. In a continuous, combined HRT regimen, dydrogesterone retards the proliferation of the endometrium so that it remains atrophic or inactive.
  

• CAS Registry Number:

  152-62-5

• Synonyms:

  ;(9b,10a)-Pregna-4,6-diene-3,20-dione;(9beta,10alpha)-Pregna-4,6-diene-3,20-dione;.DELTA.6-Retroprogesterone;10a-Isopregnenone;6-Dehydro-9.beta.,10.alpha.-progesterone;6-Dehydro-9b,10a-progesterone;6-Dehydroretroprogesterone;9b,10a-Pregna-4,6-diene-3,20-dione;9beta,10alpha-Pregna-4,6-diene-3,20-dione (8CI);D6-Retroprogesterone;(9beta,10xi)-pregna-4,6-diene-3,20-dione;

• Molecular Formula:

  C₂₁H₂₈O₂

• Molecular Weight:

  312.4458

• Molecular Structure:

  

• Company:

  Wuhan Jiaye Technology Co.,LTD     [ China ]        

• Contact:

  shirley

• Tel:

  15872388127

• Fax:

  86-27-88048077

• Email:

  shirley@ycgmp.com